BMS forms immuno-oncology collaboration with 10 US and EU cancer institutes
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb (BMS) formed the International Immuno-Oncology Network (II-ON) with 10 research centers in the US and EU as a global collaboration between industry and academia to broaden global scientific understanding of how the body's immune system can be harnessed to fight cancer.
You may also be interested in...
Bristol Teams Up With Billionaire-Backed Parker Institute On IO Research
A key goal of Bristol's second major academic research collaboration is to get trials up-and-running more quickly.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.